Stockreport

Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting

XBiotech Inc.  (XBIT) 
Last xbiotech inc. earnings: 8/9 03:01 pm Check Earnings Report
US:NASDAQ Investor Relations: xbiotech.com/about/investors.html
PDF Rapid and significant reduction in skin lesions, 66% (pEASI score in 4 and 7 weeks, respectively. Rapid and significant resolution of worst itch and pain, 57% (p Substan [Read more]